CellVoyant, founded by Rafael Carazo Salas, is a University of Bristol spinout leading a transformative approach in stem cell-based therapy manufacturing. By integrating novel technologies, CellVoyant aims to produce therapies that are efficient, safe, and tailored to individual patient needs, addressing the current slow and inefficient methods plaguing the industry.

Leveraging a combination of large-scale cell culture, live cell imaging, and data-driven computer vision, CellVoyant optimises stem cell differentiation in real time. This breakthrough allows for the precise programming of stem cells into desired adult cell types, marking a significant leap forward from traditional, error-prone methods.

Based in Bristol, UK, CellVoyant operates a hybrid model, fostering a culture of innovation and creativity among its team. With a strong focus on collaboration, diversity, and inclusivity, the company is committed to building a vibrant and impactful workplace.

CellVoyant's ethical framework is built on integrity, transparency, and accountability, principles that guide its pursuit of developing life-changing therapies. The company's successful £7.6m seed funding round reflects confidence in its potential to revolutionise stem cell therapy for conditions beyond cancer, including diabetes and potentially dementia, promising a future where effective treatments are more readily available.